The Rise of First in Class Drugs
                     The Rise of First in Class 
Drugs: What the latest 
clinical data tells us?
Introduction
In a significant paradigm shift in the pharmaceutical industry, new drugs are being developed 
that represent “first in class” medications, which have brand new mechanisms of action for 
treatment of diseases. These are not incremental or follow-on drugs, but the latest in biological 
understanding and changing the way the modern clinical drug development process should be 
done.
In recent years, the FDA has approved new products and clinical studies that are clearly signaling 
a shift towards innovation-incentivized Research and Development. The FDA has approved 37 
new drugs in 2022, which represents more than half of the first in class approvals. This is in line 
with the general trend in the pharmaceutical industry, as companies shift from incremental 
changes towards novel targets.
What does the term ‘First in Class 
Drug' mean?
Drugs with a novel mechanism of action (MoA) to treat a disease are first in class drugs. They are 
also the first treatments to be approved for a previously unexploited biological pathway.
Unlike:
• Drugs that are best in class to address the need for improvement in existing treatments 
• Follow-on drugs that mimic active drugs 
The first-in-class therapies create completely new therapeutic categories.
Understanding the role of these in the 
clinical drug development process.
First-in-class drugs go through the typical clinical stages, but with much greater uncertainty:
Focus of phase I: Safety and early biological activity, with unknown risk profiles. 
Phase II: Essential to confirm if the new mechanism can function in humans 
The efficacy of the process is confirmed in Phase III through adaptive or biomarker-driven 
designs. 
As opposed to conventional drugs, this clinical drug development process is not linear, but rather 
flexible and iterative. The study design is frequently changed during development, due to 
biomarkers, adaptive trials and real-time data.
Understanding the Role of These in 
the Clinical Drug Development Process
First-in-class drugs go through the typical clinical stages, but with much greater uncertainty:
• Phase I: Focus on safety and early biological activity, with unknown risk profiles.
• Phase II: Essential to confirm if the new mechanism can function in humans
• Phase III: Confirms efficacy using adaptive or biomarker-driven designs
Why First-in-Class Drugs Are More 
Challenging
As the name suggests, 'first-in-class' drugs are more difficult.The name 'first-in-class' says it all: 
they're harder to do.
Key challenges include:
Biological uncertainty: Targets may not act as they are supposed to do in humans
• High Phase II failure rates: Efficacy signals are weak or not consistent
Complex trial design: Needs adaptive and biomarker approaches
• Regulatory complexity: Few precedents for new mechanisms
Why First-in-Class Drugs Are More 
Challenging
As the name suggests, 'first-in-class' drugs are more difficult. The name 'first-in-class' says it all: 
they're harder to do.
Key challenges include:
•Biological uncertainty: Targets may not act as they are supposed to do in humans
•High Phase II failure rates: Efficacy signals are weak or not consistent
•Complex trial design: Needs adaptive and biomarker approaches
•Regulatory complexity: Few precedents for new mechanisms
What Is Driving Their Rise?
1. Genomics and Target Discovery
2. Precision Medicine
3. Artificial Intelligence
4. Pharma Strategy Shift
Conclusion
First-in-class drugs are changing the pharmaceutical landscape by pushing innovation beyond the 
smallest of steps to real biological breakthroughs. They're altering the clinical drug development 
process to be more data-driven, adaptive, and precision.
With these therapies will be increased scientific and regulatory risk, but also the greatest 
potential for transformative impact in medicine.
Genomics, Al and real world evidence are intertwining and first-in-class drugs will become a 
bigger part of the future of global drug development and therapeutic innovation.
WEBSITE : WWW.CLIVAL.
COM
 
• WWW.LIFESCIENCEINTELLIPEDIA.COM 
• WWW.CHEMXPERT.COM
LOCATION:- C-89, SECTOR-65 NOIDA-U.P. 201301 
(INDIA)
E-MAIL:- [email protected] | 
[email protected] 
PHONE:- +91-120-6631301-335
MOB NO:- +91-9990237670
THANK YOU